Tenon Medical, Inc. Annual Report: A Plain-English Guide

I’ve put together this guide to help you understand Tenon Medical’s performance this year. Instead of digging through dense legal filings, we’ll break down the business so you can decide if it’s the right fit for your portfolio.

1. What does this company do?

Tenon Medical makes tools for sacroiliac (SI) joint fusion, a procedure for chronic lower back pain. Their main product is the Catamaran® SI Joint Fusion System, a titanium-coated implant that stabilizes the joint. The company is currently in a "growth and investment" phase, prioritizing research and sales expansion over immediate profit. They reported a loss of about $17.5 million for the year ending December 31, 2025.

2. Major wins and changes this year

The big story for 2025 was the $10 million acquisition of the SIMPL product line from Life Spine, Inc. This move broadens their catalog beyond the Catamaran system. By adding the SIMPL system—a minimally invasive fusion solution—Tenon aims to grow its footprint in the orthopedic market. Leadership is now focused on integrating these assets, which includes aligning sales training, inventory, and surgeon adoption.

3. Financial health: The reality of issuing more shares

Tenon is not yet profitable and does not have a large cash cushion. To fund growth, they have been selling more shares and warrants to raise capital. For example, they used an "at-the-market" program to raise cash throughout the year to cover an annual spending rate of about $12 million.

This results in "dilution." Every time they issue new shares to raise cash, your slice of the ownership pie gets smaller. As of March 2026, they had about 11.3 million shares outstanding. This represents a significant increase from previous periods as the company prioritized maintaining operating cash over protecting existing ownership percentages.

4. Key risks to watch

• Cash Needs: The company is burning through cash to grow, holding about $3.2 million in cash as of their latest filing. If they cannot raise more money or quickly increase sales, they may need to secure additional funding within 12 months.
• Integration Risk: Merging the SIMPL business is a complex process. The company must ensure these new products sell well alongside the Catamaran system. If combined revenue does not grow, the acquisition could become a drain on their limited resources.
• Competitive Pressure: Tenon is a small player in a field dominated by large, well-established medical device companies. Their success depends on proving their tools are more effective or easier for surgeons to use than the alternatives.

5. Future outlook

The company is now focused on scaling its combined product line. For investors, the most important indicator is whether this acquisition leads to a significant increase in sales and moves the company toward a positive profit margin. They are betting that these new products will make them more competitive, but they have a long road ahead to prove they can build a sustainable, profitable business.

Decision Checklist:

• Risk Tolerance: Are you comfortable with a company that is currently losing money and relying on share issuance to fund its operations?
• Growth Potential: Do you believe the SIMPL acquisition will successfully capture enough market share to justify the dilution of your shares?
• Timeline: Are you prepared to hold this investment through a multi-year integration and scaling phase?